Breaking News, Collaborations & Alliances

Evotec, Boehringer Ingelheim Partner to Tackle Ophthalmologic Disorders

Aims to identify and validate promising targets and new approaches for therapeutic interventions.

Author Image

By: Charlie Sternberg

Associate Editor

Evotec SE has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent stem cell (iPSC)-based disease modelling for ophthalmologic disorders. Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions.   Through phenotypic screening of human iPSC-derived cells, supported by Evotec’s PanOmics platform, Evotec will identify small molecules able to modulate disease phe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters